URGN: UroGen Pharma Ltd Company Value to Net Income

UroGen Pharma Ltd - graphic logo of issuer URGN

UroGen Pharma Ltd. (URGN) relies on a transparent pipeline and the skilled management of the Israeli biotech firm. Its proprietary hydrogel technology enables global scaling of therapy, while efficient production outsourcing via CMOs minimizes operational risks. The historical P/E level of the company on GURU.Markets captures current valuation dynamics, where -19.80 represents the current metric level, allowing for the determination of the asset's margin of safety.

Price to Earnings Ratio: UroGen Pharma Ltd. (URGN) for 07/04/2022 - 11/16/2026

Comprehensive metric breakdowns and analytics for UroGen Pharma Ltd (URGN)

- share price and expert price forecast:
- market capitalization information:
General company analysis:URGN, UroGen Pharma Ltd
Flagship merchandise of UroGen Pharma

The P/E ratio determines the market value of a single unit of net profit, allowing an investor to assess the extent of overpayment for the business's future earnings. By analyzing the price-to-earnings ratio, the strategist compares the capitalization rates of UroGen Pharma Ltd. (URGN) with the efficiency of its scientific core and the stability of its key urology staff, which confirms the fundamental resilience of the issuer's commercial potential.

Analysis of competing companies

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|BCAX: Price to Earnings Ratio|PSNL - P/E Multiple|Erasca Corp (ERAS) - Price to Earnings Ratio|Delcath - Company Value to Net Income|YMAB (Y-mAbs Therapeutics Inc) - P/E Multiple|Market Cap to Earnings Aura Biosciences, Inc. AURA|P/E Multiple CADL|P/E Multiple Accuray (ARAY)|Price to Earnings Ratio SELLAS Life Sciences Group Inc. SLS|ACTU - Price to Earnings Ratio|CTOR: Price to Earnings Ratio|Company Value to Net Income HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Price to Earnings Ratio|Market Cap to Earnings Fate Therapeutics Corp (FATE)|Price to Earnings Ratio WHWK|Price to Earnings Multiple TCRX (TScan Therapeutics, Inc.)|P/E Multiple CSBR|XBIT - Market Cap to Earnings|CEL-SCI Corporation - Price to Earnings Ratio|Company Value to Net Income OSTX|radiopharmtheranostics.com - P/E Multiple|ARTV: Price to Earnings Ratio|ANL (adlainortye.com) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics, Inc.) - P/E Multiple|P/E Multiple xiliotx.com|Price to Earnings Ratio Enochian BioSciences (RENB)|Price to Earnings Ratio MURA (Mural Oncology PLC)|Price to Earnings Ratio Kairos Pharma Ltd KAPA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV